Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMPR1B | O00238 | 6/20 | 0.51 |
| ▸ | BMPR1A | P36894 | 6/20 | 0.51 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.51 |
| ▸ | ACVRL1 | P37023 | 6/20 | 0.51 |
| ▸ | ACVR1 | Q04771 | 6/20 | 0.51 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | HBB | P68871 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27675467 | 0.90 | BMPR1B (0.43) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL27655367 | 0.88 | CNR1 (0.44) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL27675339 | 0.88 | CNR1 (0.44) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL745614 | 0.87 | BRD4 (0.55) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL25899986 | 0.84 | BMPR1B (0.50) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL16064620 | 0.84 | SLC6A4 (0.43) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL21011997 | 0.84 | BMPR1A (0.54) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL22667292 | 0.81 | BMPR1B (0.55) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL30403475 | 0.81 | BMPR1B (0.55) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL31356492 | 0.81 | BMPR1B (0.46) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-11160797-B2 | Pyridinone derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG (CH) | 2021-11-02 | — | — | US | disclosed |
| US-20200360357-A1 | Pyridinone derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG (CH) | 2020-11-19 | — | — | US | disclosed |
| CN-1934114-A | Substituted sym-triindole | IHARA CHEMICAL IND CO (JP) | 2007-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | BMPR1B 2037/4885BMPR1A 1194/4885TGFBR1 463/4885 |
| US-20200360357-A1 | Pyridinone derivatives and their use as selective ALK-2 inhibitors | ALK, ACVR2B, ACVR1B | BMPR1B 637/4885BMPR1A 1313/4885TGFBR1 51/4885 |
| US-11160797-B2 | Pyridinone derivatives and their use as selective ALK-2 inhibitors | ALK, ACVR2B, ACVR1B | BMPR1B 637/4885BMPR1A 1313/4885TGFBR1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.